New “Buy” Rating Was Given to VolitionRX (AMEX:VNRX)

May 23, 2018 - By sdfsdfsdf

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 5.80, from 7 in 2017Q3. It is negative, as 3 investors sold VolitionRx Limited shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 4.52 million shares or 51.36% less from 9.30 million shares in 2017Q3 were reported.

Northern reported 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Garrison Bradford Associate accumulated 15,500 shares or 0.04% of the stock. Bank Of Ny Mellon Corporation reported 10,335 shares. Bessemer Grp holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 10,000 shares. Royal Savings Bank Of Canada reported 0% stake. Geode Capital Mgmt Lc holds 100,890 shares. Knoll Capital Mgmt Lp invested in 0.91% or 351,538 shares. Vanguard Gp stated it has 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Brown Brothers Harriman And holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 3,823 shares. Lagoda Inv Mngmt L P invested in 3.94% or 3.52M shares. Creative Planning invested in 13,200 shares or 0% of the stock. Morgan Stanley has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX) for 63,400 shares. Leisure Capital Mngmt owns 74,863 shares. Blackrock has 11,219 shares. Bridgeway Capital invested in 0% or 109,400 shares.

Why Has Oppenheimer Given VolitionRX (AMEX:VNRX) a $7.0000 Price Target

Analysts at Oppenheimer has a key “Buy” rating for VolitionRX (AMEX:VNRX). The firm started coverage in analysts report published on 23 May. The target price per share suggests upside of 192.89 % from the previous close.

VolitionRx Limited (NYSEAMERICAN:VNRX) Ratings Coverage

Among 2 analysts covering VolitionRX (AMEX:VNRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VolitionRX has $10.0 highest and $6 lowest target. $8’s average target is 234.73% above currents $2.39 stock price. VolitionRX had 4 analyst reports since January 29, 2018 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $10.0 target in Tuesday, February 6 report. As per Monday, January 29, the company rating was maintained by H.C. Wainwright. On Monday, March 5 the stock rating was maintained by H.C. Wainwright with “Buy”.

The stock increased 6.70% or $0.15 during the last trading session, reaching $2.39. About 254,643 shares traded or 84.00% up from the average. VolitionRx Limited (AMEX:VNRX) has declined 42.82% since May 23, 2017 and is downtrending. It has underperformed by 54.37% the S&P500.

Analysts await VolitionRx Limited (NYSEAMERICAN:VNRX) to report earnings on August, 8. They expect $-0.17 earnings per share, down 30.77 % or $0.04 from last year’s $-0.13 per share. After $-0.17 actual earnings per share reported by VolitionRx Limited for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $71.77 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.